China Meheco Group Co.Ltd(600056) : covid-19 virus treatment drug related business has no significant impact on the company's recent operating performance
E company, China Meheco Group Co.Ltd(600056) ( China Meheco Group Co.Ltd(600056) ) announced March 14th that the company signed an agreement with Pfizer Inc in March 9, 2022 and will be responsible for the commercial operation of Pfizer Inc COVID-19 virus treatment drug PAXLOVID in the Chinese mainland market during the agreement period (2022). This product is a prescription drug, which has not yet entered the national medical insurance and China covid-19 pneumonia diagnosis and treatment plan. The final use and sales are affected by epidemic prevention and control and other factors, and it is expected that the relevant business scale accounts for a small proportion of the company's overall business volume, which has no significant impact on the company's recent operating performance.
Shaanxi Jinye Science Technology And Education Group Co.Ltd(000812) : the person acting in concert of the controlling shareholder intends to reduce the holding of no more than 2.1% shares
E company news, Shaanxi Jinye Science Technology And Education Group Co.Ltd(000812) ( Shaanxi Jinye Science Technology And Education Group Co.Ltd(000812) ) announced on March 14 that Chongqing jinjiaxing, the controlling shareholder and actual controller of the company, plans to reduce its holdings of no more than 16.16 million shares of the company by means of centralized bidding or block trading in the next six months, that is, no more than 2.10% of the current total share capital of the company.
Luxshare Precision Industry Co.Ltd(002475) : net profit in the first quarter increased by 25% - 30%
E company news, Luxshare Precision Industry Co.Ltd(002475) ( Luxshare Precision Industry Co.Ltd(002475) ) released the performance forecast on March 14. It is estimated that the net profit attributable to the parent company in the first quarter of 2022 will be 1.686 billion yuan - 1.754 billion yuan, with a year-on-year increase of 25% - 30%.
Wanhua Chemical Group Co.Ltd(600309) : the net profit in 2021 increased by 145% year-on-year, and it is proposed to pay 25 yuan in 10
E company news, Wanhua Chemical Group Co.Ltd(600309) ( Wanhua Chemical Group Co.Ltd(600309) ) disclosed its annual report on March 14. The operating revenue in 2021 was 145538 billion yuan, a year-on-year increase of 98.19%; The net profit was 24.649 billion yuan, a year-on-year increase of 145.47%; The basic earnings per share is 7.85 yuan. It is proposed to pay a cash dividend of 25 yuan (including tax) for every 10 shares.
Hangzhou Dadi Haiyang Environmental Protection Co.Ltd(301068) : the company and its subsidiaries affected by the epidemic stopped production
E company news, Hangzhou Dadi Haiyang Environmental Protection Co.Ltd(301068) ( Hangzhou Dadi Haiyang Environmental Protection Co.Ltd(301068) ) announced on March 14 that the company and its wholly-owned subsidiary Shengtang environmental protection actively responded to the government's epidemic prevention policy, obeyed the management of relevant departments, advocated online office and home office, and began to stop production in an orderly manner according to the spirit of the document recently. Some of the company stopped production, and Shengtang environmental protection stopped production in an all-round way, so as to fully cooperate with the government's epidemic prevention work, Curb the spread and spread of the epidemic. The resumption time will be determined by relevant departments according to the situation of epidemic prevention and control.
Linewell Software Co.Ltd(603636) : electronic license projects account for a relatively small proportion of the company's revenue
E company news, Linewell Software Co.Ltd(603636) ( Linewell Software Co.Ltd(603636) ) issued a change announcement on March 14. The company is concerned about media reports that the company is involved in electronic license business. In 2020, the electronic license project of the company accounted for a relatively small proportion of the annual operating revenue, which did not have a significant impact on the production and operation of the company.
Yixintang Pharmaceutical Group Co.Ltd(002727) performance express: net profit of RMB 921 million in 2021, with a year-on-year increase of 16.65%
E company news, Yixintang Pharmaceutical Group Co.Ltd(002727) ( Yixintang Pharmaceutical Group Co.Ltd(002727) ) released the performance express on March 14. The operating revenue in 2021 was 14.585 billion yuan, a year-on-year increase of 15.24%; The net profit attributable to the parent company was 921 million yuan, a year-on-year increase of 16.65%; The basic earnings per share is 1.56 yuan. In 2021, the company's businesses developed steadily. As of December 31, 2021, the company had 8560 direct chain stores, with a net increase of 1355 throughout the year.
Ganfeng Lithium Co.Ltd(002460) performance express: net profit of RMB 5.175 billion in 2021, with a year-on-year increase of 405.03%
E company news, Ganfeng Lithium Co.Ltd(002460) ( Ganfeng Lithium Co.Ltd(002460) ) disclosed the performance express of 2021 on March 14. During the reporting period, the company achieved an operating revenue of 11.162 billion yuan, a year-on-year increase of 102.07%; The net profit was 5.175 billion yuan, a year-on-year increase of 405.03%; The basic earnings per share is 3.66 yuan. With the rapid development of new energy vehicles and energy storage industry, the demand of downstream customers for lithium products has increased strongly. In 2021, the production and sales volume of lithium products of the company increased, and the average sales price of products increased significantly compared with that in 2020.
Jiangsu Sinopep-Allsino Biopharmaceutical Co.Ltd(688076) : the company did not provide covid-19 pharmaceutical intermediate
E company news, Jiangsu Sinopep-Allsino Biopharmaceutical Co.Ltd(688076) ( Jiangsu Sinopep-Allsino Biopharmaceutical Co.Ltd(688076) ) issued a change announcement on March 14. Recently, The company is concerned about the online report that "yanyeyi covid-19 drug encitrelvir intermediate supplier Jiangsu Sinopep-Allsino Biopharmaceutical Co.Ltd(688076) , yanyeyi drug intermediates are mainly polypeptides, while Nuotai is the main manufacturer of polypeptide intermediates and APIs, and the only listed company with yanyeyi covid-19 drug intermediates in the public data". For the above report, the company clarifies as follows: 1 At present, the company has carried out the research and development of intermediates mentioned in the report and has the supply capacity of small batches in the research and development laboratory, but has not yet carried out commercial production; 2. As of the date of this announcement, the company has not provided the above intermediates to yanyeyi pharmaceutical company of Japan.
